Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

The follow-up of the pivotal trial and large case series reports of a proportion of patients, between 5% and 9%, with relapsed or refractory Hodgkin lymphoma failing autologous stem cell transplantation and treated with brentuximab vedotin, achieving and maintaining long lasting complete responses with no further treatment. Very long-term data on the outcomes of such patients are indeed underreported. Our institutional experience with patients meeting these characteristics and in continuous complete response for more than 5 years after brentuximab vedotin was reviewed. Five patients achieved a median duration of complete response of 7.4 (range 5.1-8.1) years, and none of them encountered disease relapse or received any subsequent consolidation, including allogeneic transplantation. A proportion of patients failing autologous transplantation and receiving subsequent brentuximab vedotin may reach a long-lasting complete response with no need of further treatment. These patients are therefore considered cured. The role of allogeneic transplantation in such patients is matter of debate.


Alessandro Broccoli, Lisa Argnani, Paolo Elia Coppola, Marianna Gentilini, Gianmarco Bagnato, Ginevra Lolli, Matteo Carella, Laura Nanni, Alice Morigi, Beatrice Casadei, Cinzia Pellegrini, Vittorio Stefoni, Pier Luigi Zinzani. Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series. Tumori. 2023 Apr;109(2):249-252

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 35441544

View Full Text